Clinical • Enrollment change • Trial primary completion date • Combination therapy
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
|
HER-2 negative • ER negative • PGR negative
|
budigalimab (ABBV-181) • livmoniplimab (ABBV-151)